Survival Analysis of Symptomatic COVID-19 in Phuentsholing Municipality, Bhutan.
Bhutan
COVID-19
analysis
patients
survival
symptomatic
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
18 10 2021
18 10 2021
Historique:
received:
22
09
2021
revised:
14
10
2021
accepted:
15
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
29
10
2021
Statut:
epublish
Résumé
COVID-19 is a disease that is caused by a highly transmissible and pathogenic novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). All of the COVID-19 positive cases in Bhutanese travellers returning via the Phuentsholing point of entry, the local population, and Indian nationals were isolated in the Phuentsholing COVID-19 isolation ward, Bhutan. This study aimed to identify the risk factors for developing symptoms among COVID-19 positive patients in this ward. A retrospective cohort study was conducted using the data regarding COVID-19 positive cases in the Phuentsholing COVID-19 isolation ward from 28 May 2020 to 31 May 2021. The Cox proportional hazards regression model was used to identify the risk factors of developing COVID-19 symptoms. There were 521 patients in the study; 368 (70.6%) were males and 153 (29.4%) were females. The mean age was 32 years (with a range of 1-78 years), and 290 (56.0%) reported at least one symptom. The median length of isolation was eight days (with a range of 3-48 days). The common symptoms were: cough (162, 31.0%), fever (135, 26.0%), and headache (101, 19.0%). In the multivariable Cox regression, vaccinated patients were 77.0% (
Identifiants
pubmed: 34682676
pii: ijerph182010929
doi: 10.3390/ijerph182010929
pmc: PMC8535658
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Occup Med (Lond). 2020 Mar 12;70(1):3-5
pubmed: 32107548
Am J Ind Med. 2021 Apr;64(4):227-237
pubmed: 33491195
Int J Environ Res Public Health. 2021 Jan 05;18(1):
pubmed: 33466497
PLoS One. 2020 May 19;15(5):e0233588
pubmed: 32428031
Mol Ther Methods Clin Dev. 2020 Jun 24;18:367-375
pubmed: 32665963
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
Lancet. 2020 May 23;395(10237):1593-1595
pubmed: 32416788
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
IEEE Access. 2020 Aug 19;8:154087-154094
pubmed: 34786285
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Netw Open. 2021 Jun 1;4(6):e2115985
pubmed: 34097044
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
BMJ. 2020 Apr 30;369:m1794
pubmed: 32354787
Expert Rev Vaccines. 2021 Oct;20(10):1201-1209
pubmed: 34488546
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
J Med Internet Res. 2020 Jun 30;22(6):e19636
pubmed: 32544071
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Cureus. 2020 Mar 26;12(3):e7423
pubmed: 32337143
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
BMJ Glob Health. 2021 May;6(5):
pubmed: 34006520